Sarcoma  >>  pegylated liposomal doxorubicin  >>  Phase 2
Welcome,         Profile    Billing    Logout  

14 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pegylated liposomal doxorubicin / Generic mfg.
NCT00003334: Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract

Completed
2
US
paclitaxel, pegylated liposomal doxorubicin hydrochloride
NYU Langone Health, National Cancer Institute (NCI)
Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma
12/01
 
NCT00020449: Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma

Completed
2
US
recombinant interleukin-12, paclitaxel, pegylated liposomal doxorubicin hydrochloride
National Cancer Institute (NCI)
Sarcoma
 
05/04
NCT00005643: Chemotherapy in Treating Patients With Sarcoma of the Uterus

Completed
2
US, Canada
pegylated liposomal doxorubicin hydrochloride
Gynecologic Oncology Group, National Cancer Institute (NCI)
Endometrial Cancer, Sarcoma
03/05
 
PaLiDo, NCT00861120 / 2008-007799-13: Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type

Checkmark P2 data
Dec 2012 - Dec 2012: P2 data
Checkmark P2 data - ASCO
Jun 2012 - Jun 2012: P2 data - ASCO
Completed
2
33
Europe
Pegylated liposomal doxorubicin, Caelyx, Panitumumab, Vectibix
Vejle Hospital
Epithelial Ovarian Cancer
08/11
08/12
NCT00815945 / 2008-000245-55: Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors

Completed
2
41
Europe
PegLiposomal Doxorubicin, Caelyx, Carboplatin
AGO Study Group, Merck Sharp & Dohme LLC
Mesenchymal Tumor, Carcinosarcoma, Leiomyosarcoma
11/11
01/12
NCT00923936: Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma

Completed
2
16
US
Liposomal Doxorubicin, Doxil, Bevacizumab, Avastin
National Cancer Institute (NCI)
Sarcoma, Kaposi
05/15
11/17
NCT03268772: PLD and IFO As First-line Treatment for Patients With Advanced or Metastatic STS

Unknown status
2
40
RoW
PLD and IFO
Fudan University
Soft Tissue Sarcoma
11/20
12/20
NCT04765228: Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma

Recruiting
2
45
RoW
Pegylated liposomal doxorubicin, Anlotinib
Yong Chen
Stage III Adult Soft Tissue Sarcoma
12/22
12/22
Actuate 1801, NCT03678883: 9-ING-41 in Patients With Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc.
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
11/24
11/25
NCT02364713: MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Active, not recruiting
2
66
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, MV-NIS, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Quality-of-Life Assessment, Quality of Life Assessment, Topotecan Hydrochloride, Hycamptamine, Hycamtin, SKF S-104864-A, Topotecan HCl, topotecan hydrochloride (oral)
Mayo Clinic, National Cancer Institute (NCI)
Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
03/27
02/28
NCT00032162: Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer

Completed
1/2
63
Europe
carboplatin, pegylated liposomal doxorubicin hydrochloride
AGO Study Group
Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma
05/05
 
NCT00949325: Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark Temsirolimus+Liposomal doxorubicin
Feb 2013 - Feb 2013: Temsirolimus+Liposomal doxorubicin
Completed
1/2
24
US
temsirolimus plus liposomal doxorubicin, Torisel, Doxil
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Comprehensive Cancer Network, Wyeth is now a wholly owned subsidiary of Pfizer
Sarcoma
09/12
09/12
PembroPlus, NCT02331251: Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer

Checkmark AACR-NCI-EORTC 2015
Oct 2015 - Oct 2015: AACR-NCI-EORTC 2015
Checkmark IASLC-WCLC 2015
Aug 2015 - Aug 2015: IASLC-WCLC 2015
Terminated
1/2
81
US
Pembrolizumab, Keytruda, Gemcitabine, Gemzar, Docetaxel, Taxotere, Nab-paclitaxel, Abraxane, Vinorelbine, Navelbine, Irinotecan, Camptosar, Liposomal Doxorubicin, Doxil
Western Regional Medical Center
Advanced Cancer, Breast Cancer, Sarcoma, Pancreatic Cancer, Small Cell Lung Cancer, Ovarian
01/18
01/18
RAPID, NCT05774275: The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma

Recruiting
1/2
52
RoW
Pegylated Liposomal Doxorubicin, Doxil, Doxorubicin, Doxorubicin Hydrochloride, Anti-PD-1 monoclonal antibody, Sintilimab, Radiotherapy
Fudan University
High-Risk Localized Soft Tissue Sarcoma
08/24
08/29

Download Options